Extramedullary orbital granulocytic sarcoma without bone marrow involvement: a report of two cases

Pediatr Hematol Oncol. 2011 Feb;28(1):65-70. doi: 10.3109/08880018.2010.511439. Epub 2010 Sep 23.

Abstract

The authors present herein 2 extramedullary orbital granulocytic sarcoma (GS) cases without bone marrow involvement in view of their rarity and also to reevaluate the treatment approach in this disease. Seven days of high-dose methyl prednisolone (HDMP) treatment (3 days 30 mg/kg/day and 4 days 20 mg/kg/day) was administered initially, and subsequently Acute Myeloid Leukaemia-Berlin Frankfurt Münster (AML-BFM) 2004 treatment protocol was continued for 2 cases. Eye findings of the cases resolved considerably with HDMP treatment. They have still been under systemic chemotherapy without any complication for 1 year. Thus, early diagnosis and AML-targeted intensive chemotherapy improve the prognosis of GS even if there is no bone marrow involvement.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / drug therapy*
  • Magnetic Resonance Imaging
  • Prednisolone / administration & dosage
  • Prednisolone / therapeutic use*
  • Prognosis
  • Sarcoma, Myeloid / diagnosis
  • Sarcoma, Myeloid / drug therapy*

Substances

  • Prednisolone